The content on this site is intended for healthcare professionals only
Dr Woyach speaks with ecancertv at ASH 2016 about outcomes from RESONATE 1 2, finding ibrutinib suitable for patients of all ages, and how to treat when ibrutinib fails.
She discusses age-related toxicity and discontinuation of ibrutinib, especially in older and treatment naive patients, and introduces a CD19 antibody called MOR208 for patients with ibrutinib resistance mutations.
Dr Woyach considers the mutational drivers behind resistance, detectable in blood samples ahead of relapse, and how this might be a stage for pre-emptive intervention.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Best practice in precision medicine for prostate cancer
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
